Amer Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, New Haven, CT, discusses the use of of glasdegib, a Hedgehog pathway inhibitor, in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes, acute myeloid leukemia and chronic myelomonocytic leukemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).